Kuruppu, Darshini http://orcid.org/0000-0003-0075-9685
Bhere, Deepak http://orcid.org/0000-0003-4142-5518
Farrar, Christian T. http://orcid.org/0000-0001-6623-8220
Shah, Khalid http://orcid.org/0000-0002-5474-0974
Brownell, Anna-Liisa
Mahmood, Umar
Tanabe, Kenneth K.
Funding for this research was provided by:
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-11-1-0388)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R21CA186054-01)
Massachusetts General Hospital (ESCCO-Breast Cancer Research Fund)
Article History
Received: 16 June 2022
Revised: 28 November 2022
Accepted: 13 January 2023
First Online: 1 February 2023
Change Date: 8 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41417-023-00601-6
Competing interests
: D.B. owns equity and is consultant at AMASA Therapeutics Inc., a biotechnology company for cell-based therapeutics for cancer. The other authors declare no conflicting interests.
: Experiments were conducted under Institutional Animal Care and Use Committee (IACUC) for Massachusetts General Hospital (MGH) guidelines. Animal procedures were performed at an AAALAC-accredited facility and animals were cared for in accordance with the Guide for the Care and Use of Laboratory Animals. All research protocols were approved by the IACUC”.